Universal reference book for medicines
Name of the drug: LIRASEPT (LIRASEPT)

Active substance: nelfinavir

Type: Antiviral drug active against HIV

Manufacturer: IRVIN 2 (Russia) manufactured by LOK-BETA PHARMACEUTICALS (I) (India)
Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

PHARMACHOLOGIC EFFECT
An antiviral agent.
It binds to the active site of the HIV protease. Prevents the splitting of polyproteins, which leads to the formation of immature viral particles, unable to infect other cells, slows the progression of the disease.
It exhibits synergism and has an additive effect on HIV as a component of double and triple combined regimens, which include zidovudine, lamivudine, didanosine, zalcitabine, stavudine, and transcriptase inhibitors, without enhancing the cytotoxicity of the latter.

PHARMACOKINETICS
After intake, absorption is 78%.
At reception during meal S max and AUC in 2 times more than after reception on an empty stomach. The increase in plasma concentration after ingestion during meals does not depend on the fat content of the food.
Binding to plasma proteins - 98%.

Metabolised in the liver with the participation of isoenzymes of the cytochrome P 450 system by oxidation, with the formation of major and minor metabolites with pharmacological activity.

T 1/2 in the terminal phase is 2.5-5 hours. It is excreted with feces 87%, with urine 1-2%.

INDICATIONS
Treatment of infection caused by HIV-1 (as part of combination therapy).

DOSING MODE
Individual, depending on the age and scheme of therapy.

SIDE EFFECT
Possible: skin rash, diarrhea, flatulence, nausea, abdominal pain, asthenia, neutropenia, lymphocytosis, increased activity of CK, ALT, bleeding, spontaneous subcutaneous hematoma, hemarthrosis (in patients with hemophilia).

CONTRAINDICATIONS
Hypersensitivity to nelfinavir.

PREGNANCY AND LACTATION
Application in pregnancy and lactation (breastfeeding) is possible in cases where the expected benefit of therapy for the mother exceeds the potential risk to the fetus or infant.

APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Use with caution for violations of liver function.

SPECIAL INSTRUCTIONS
Use with caution in hemophilia, liver function disorders, in combination with CYP3A isoenzyme inducers or with potentially toxic drugs that are metabolized with the participation of these isoenzymes.

DRUG INTERACTION
When used simultaneously with ritonavir, indinavir, AUC and T 1/2 of nelfinavir increase.

Nelfinavir increases the AUC of saquinavir 4-fold.

With the simultaneous use with inductors of microsomal liver enzymes (including rifamycin, nevirapine, phenobarbital, phenytoin, carbamazepine), a decrease in the concentration of nelfinavir in the blood plasma is possible.

Nelfinavir increases plasma concentrations of terfenadine, astemizole, cisapride, and calcium channel blockers.
Nelfinavir increases the duration of action of midazolam and triazolam.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!